Diana Chirovsky - Center for Observational and Real World Evidence, Merck & Co., Inc

基本信息

浏览量：0

职业迁徙

个人简介

暂无内容

研究兴趣

论文共 46 篇作者统计合作学者相似作者

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

Real-world Neoadjuvant Treatment Patterns and Outcomes in Resected Non-Small Cell Lung Cancer

Jessica Donington,Xiaohan Hu,Su Zhang,Yan Song,Ashwini Arunachalam,Diana Chirovsky,Chi Gao,Ari Lerner,Anya Jiang,James Signorovitch,Ayman Samkari

CLINICAL LUNG CANCERno. 5 (2024): 440-448

引用0浏览0WOS引用

Network Meta-Analysis of Pembrolizumab As Monotherapy and in Combination with Chemotherapy for First-Line Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Ali Mojebi, Karthik Ramakrishnan,Dieter Ayers,Sam Keeping,Rebekah Borse,Diana Chirovsky

Jornal Brasileiro de Economia da Saúdeno. 1 (2024): 25-64

引用0浏览0引用

A Retrospective Analysis of Treatment Patterns, Overall Survival, and Real-World Disease-Free Survival in Early-Stage Non-Small Cell Lung Cancer Following Complete Resection

Xiaohan Hu,Diana Chirovsky,Mark S. Walker, Yuexi Wang,Alpana Kaushiva, Jon Tepsick,Ayman Samkari

BMC PULMONARY MEDICINE（2024）

引用0浏览0WOS引用

5-Year Real-World Outcomes with Frontline Pembrolizumab Monotherapy in PD-L1 Expression ≥ 50% Advanced NSCLC

Vamsidhar Velcheti,Pragya Rai,Yu-Han Kao,Diana Chirovsky, Ana Tablante Nunes,Stephen Liu

CLINICAL LUNG CANCERno. 6 (2024)

引用0浏览0WOS引用

First-line Treatment Patterns and Outcomes in Advanced Non-Small Cell Lung Cancer in Sweden: A Population-based Real-world Study with Focus on Immunotherapy

Gunnar Wagenius,Anders Vikstrom,Anders Berglund,Stina Salomonsson,Goran Bencina,Xiaohan Hu,Diana Chirovsky,Hans Brunnstrom

ACTA ONCOLOGICA (2024): 198-205

引用0浏览0WOS引用

Phase III KEYNOTE-789 Study of Pemetrexed and Platinum with or Without Pembrolizumab for Tyrosine Kinase Inhibitor‒Resistant, EGFR-Mutant, Metastatic Nonsquamous Non-Small Cell Lung Cancer

Journal of clinical oncology official journal of the American Society of Clinical Oncologypp.JCO2302747-JCO2302747, (2024)

引用0浏览0WOS引用

Event-free Survival As a Predictor of Overall Survival and Recurrence Burden of Patients with Non-Small Cell Lung Cancer Receiving Neoadjuvant Therapy

Jessica Donington,Xiaohan Hu,Su Zhang,Yan Song,Ashwini Arunachalam,Diana Chirovsky,Chi Gao,Ari Lerner,Anya Jiang,James Signorovitch,Ayman Samkari

JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY（2024）

引用0浏览0WOS引用

Real-World Patient Characteristics, Biomarker Testing, and Adjuvant Therapy for Resected NSCLC at US Oncology Clinics, 2019-2023

Xiaohan Hu, Yu -Han Kao, Ashwini Arunachalam,Diana Chirovsky,Ayman Samkari

JOURNAL OF THORACIC ONCOLOGYno. 7 (2024): E2-E3

引用0浏览0引用

HSR24-161: Biomarker Testing, Surgical Outcomes, and Adjuvant Therapy Rates among Patients with Resected Non–Small Cell Lung Cancer (NSCLC) in the Community Setting in the United States (US), 2019–2023

Xiaohan Hu,Yu-Han Kao,Ashwini Arunachalam,Diana Chirovsky, Yiru Wang,Chenan Zhang,Kaitlyn Kane,Ayman Samkari

Journal of the National Comprehensive Cancer Networkno. 2.5 (2024)

引用0浏览0WOS引用

OA01.07 Real-World Patient Characteristics, Biomarker Testing, and Adjuvant Therapy for Resected NSCLC at U.S. Oncology Clinics, 2019-2023

Xiaohan Hu,Yu-Han Kao,Ashwini Arunachalam,Diana Chirovsky,Ayman Samkari

Journal of Thoracic Oncologyno. 7 (2024): e2-e3

引用0浏览0引用

加载更多

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

暂无相似学者，你可以通过学者研究领域进行搜索筛选

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn